"A
cute" or worsening heart failure (HF) has traditionally been synonymous with an episode of hospital-based care (1) . Acute HF has also been hypothesized to be a distinct biological entity, a concept supported by biomarkers showing end-organ injury and outcomes data showing higher post-discharge mortality rates (2-4).
However, with accumulating research, reconciling how a location of care (i.e., the hospital) could be consistently linked to a biological process (i.e., worsening heart failure [WHF]) has proven problematic (5) . A generation of randomized controlled trials using short-term intravenous (IV) therapies given soon after presentation to the hospital has failed to improve long-term outcomes (6) . Biomarker evidence of new end-organ injury (e.g., elevated troponin level) has been shown to be nonspecific to the hospitalized period (7) . Perhaps most provocative, recent outcome data suggest that patients with WHF carry a similarly poor prognosis irrespective of whether they are hospitalized (8, 9) .
With data increasingly challenging the biological relevance of the hospital in WHF, hospitalization may be more simply viewed as a treatment strategy and health care resource rather than a biological event. In that respect, as clinicians, researchers, and health systems work to decrease the burden of HF hospitalizations, key questions must be increasingly considered: What makes the hospital care strategy so special? What are the specific unique features hospitalization brings to WHF care? Answers to these questions are fundamental to efforts toward offering comparable care in the outpatient setting.
Although hospitalization is undoubtedly necessary for many patients with WHF (e.g., cardiogenic shock, unstable arrhythmia), United States registry data suggest that >90% of patients receive IV diuretic agents, with most receiving no other IV therapy (10) . Indeed, the most obviously "special" characteristic of the hospital may be that it offers the option to receive IV loop diuretic therapy, which is known to be more effective at managing congestion than escalating doses of oral diuretic agents (11) . In many circum- Science author instructions page. Greene and Felker
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